论文部分内容阅读
目的:研究P16、P15、Smad7和TGF-β1在宫颈癌中的表达,研究其在不同临床病理特征中的意义。方法:选取三峡大学医学院自2008年1月～2010年5月收集的76例宫颈癌标本作为实验组,以50例正常宫颈组织作为对照组,采用免疫组织化学技术,分别检测P16、P15、Smad7及TGF-β1在两组中的表达情况,以及在肿瘤不同临床病理特征之间的关系。结果:①P16及P15蛋白在宫颈癌组织中的表达率与正常宫颈组织中P16、P15的表达率比较,差异具有统计学意义(P<0.05);②P16、P15蛋白的阳性表达率与宫颈组织的病理学分级具有相关性,P16、P15在宫颈癌Ⅰ级中的阳性表达率明显高于Ⅱ级和Ⅲ级;③Smad7、TGF-β1在宫颈癌组织中表达的阳性率明显高于对照组(P<0.05),同时Smad7、TGF-β1的表达与宫颈癌的临床分期及淋巴结转移密切相关(P<0.05)。结论:P16、P15、Smad7、TGF-β1的表达与宫颈癌的发生和进展有一定的相关性,其表达的降低或缺失在宫颈癌的发展过程中具有协同作用,检验P16、P15、Smad7、TGF-β1的表达可以作为判定宫颈癌危险程度的指标,为正确的评估宫颈癌患者的预后提供依据。
PURPOSE: To study the expression of P16, P15, Smad7 and TGF-β1 in cervical cancer and to study their clinical significance. Methods: Totally 76 cervical cancer specimens collected from the School of Medicine, Sanxia University from January 2008 to May 2010 were selected as experimental group and 50 normal cervical tissues as control group. Immunohistochemistry was used to detect the expression of P16, P15, Smad7 and TGF-β1 expression in both groups, as well as the relationship between the different clinicopathological features of the tumor. Results: ① The positive rates of P16 and P15 in cervical cancer tissues were significantly higher than those in normal cervical tissues (P <0.05); ② The positive rates of P16 and P15 were significantly correlated with the expressions of P16 and P15 in cervical tissues The positive rates of P16 and P15 in grade Ⅰ cervical cancer were significantly higher than those in grade Ⅱ and Ⅲ. The positive rates of Smad7 and TGF-β1 in cervical cancer were significantly higher than those in control group (P <0.05). Meanwhile, the expression of Smad7 and TGF-β1 was closely related to the clinical stage and lymph node metastasis of cervical cancer (P <0.05). Conclusion: The expressions of P16, P15, Smad7 and TGF-β1 are correlated with the occurrence and progression of cervical cancer. The decrease or deletion of the expression of P16, P15, Smad7 and TGF-β1 has a synergistic effect in the development of cervical cancer. The expression of TGF-β1 can be used as an index to judge the risk of cervical cancer and provide the basis for the correct assessment of the prognosis of patients with cervical cancer.